Merck & Co.
AWARDS
NEWS
Moving into the holidays and the fast-approaching end of the year, the U.S. Food and Drug Administration (FDA) got busy wrapping up a number of to-do items. Here’s a look.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
JOBS
IN THE PRESS